Central Nervous System Pharmacology Practice Questions

Q: Which anti-epileptic drug can be safely used in pregnancy?

Lamotrigine. The management of epilepsy in pregnancy requires balancing maternal seizure control with the risk of teratogenicity. **Lamotrigine** is considered one of the safest anti-epileptic drugs (AEDs) during pregnancy [1] because it has a significantly lower risk of major congenital malformations (approx. 2–3%) compared to older AEDs. It is not associated with a specific "syndrome" of defects, though clinicians must monitor serum levels closely as clearance increases during pregnancy. **Analysis of Incorrect Options:** * **Valproic acid (Option A):** This is the **most teratogenic** AED. It is associated with a high risk of neural tube defects (e.g., spina bifida) and impaired cognitive development (lower IQ) in the offspring [1]. It is strictly avoided in pregnancy unless no other drug works. * **Phenytoin (Option B):** Causes **Fetal Hydantoin Syndrome**, characterized by craniofacial dysmorphism (cleft lip/palate), hypoplastic phalanges/nails, and microcephaly. * **Carbamazepine (Option C):** Associated with an increased risk of neural tube defects and craniofacial abnormalities, though the risk is lower than with Valproate. **NEET-PG High-Yield Pearls:** * **Safest AEDs in pregnancy:** Lamotrigine and Levetiracetam. * **Drug of choice for seizures in pregnancy:** If a patient is already well-controlled on a drug (except Valproate), it is usually continued at the lowest effective dose. * **Folic Acid Supplementation:** All pregnant women on AEDs should take high-dose folic acid (5 mg/day) to reduce the risk of neural tube defects. * **Vitamin K:** Enzyme-inducing AEDs (Phenytoin, Carbamazepine, Phenobarbital) can cause neonatal hemorrhage; Vitamin K is administered to the mother in the last month of pregnancy and to the newborn at birth [1].

Q: All of the following adverse effects are associated with carbamazepine except?

Decrease in antidiuretic hormone. **Explanation:** The correct answer is **C (Decrease in antidiuretic hormone)** because Carbamazepine actually causes an **increase** in the action of Antidiuretic Hormone (ADH). **1. Why Option C is correct:** Carbamazepine acts as an ADH enhancer by increasing the sensitivity of renal tubules to ADH and stimulating its release. This leads to water retention and **dilutional hyponatremia** (SIADH-like picture). Therefore, saying it causes a "decrease" in ADH is physiologically incorrect. **2. Why other options are incorrect:** * **A. Teratogenicity:** Carbamazepine is a known teratogen associated with **neural tube defects** (e.g., spina bifida) due to interference with folate metabolism. * **B. Neurotoxicity:** Dose-related neurotoxicity is common, manifesting as diplopia, ataxia, vertigo, and sedation. * **C. Hypersensitivity:** It can cause various skin reactions, ranging from mild rashes to life-threatening **Stevens-Johnson Syndrome (SJS)** or Toxic Epidermal Necrolysis (TEN), particularly in patients with the **HLA-B*1502** allele. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Blocks voltage-gated sodium channels in the inactivated state. * **Drug of Choice (DOC):** It remains the DOC for **Trigeminal Neuralgia**. * **Auto-induction:** Carbamazepine induces its own metabolism (CYP3A4 inducer), meaning the half-life decreases after chronic administration. * **Hematological Side Effect:** It can cause rare but serious **aplastic anemia** and agranulocytosis; baseline CBC is often recommended. * **Mnemonic (ADVERSE):** **A**taxia, **D**iplopia/Dizziness, **V**ertigo, **E**nzyme induction, **R**ash, **S**IADH, **E**pigenetic (Teratogenic).

Q: Which drug is primarily used in the management of Alzheimer's disease?

Rivastigmine. **Explanation:** **Rivastigmine** is the correct answer because it is a centrally acting, reversible acetylcholinesterase inhibitor (AChEI) that effectively crosses the blood-brain barrier. In Alzheimer’s disease, there is a progressive loss of cholinergic neurons in the nucleus basalis of Meynert. By inhibiting the breakdown of acetylcholine in the synaptic cleft, Rivastigmine enhances cholinergic neurotransmission, thereby improving cognitive function and slowing the progression of symptoms. **Analysis of Options:** * **Tacrine (A):** Although it was the first AChEI approved for Alzheimer’s, it is no longer used clinically due to significant **hepatotoxicity** and the requirement for frequent dosing. * **Pyridostigmine (C):** This is a quaternary ammonium compound that does not cross the blood-brain barrier. It is primarily used in the management of **Myasthenia Gravis** due to its longer duration of action compared to Neostigmine. * **Neostigmine (D):** Like Pyridostigmine, it is a polar quaternary amine with poor CNS penetration. It is used for reversing neuromuscular blockade (post-surgery), Myasthenia Gravis, and paralytic ileus. **Clinical Pearls for NEET-PG:** * **Rivastigmine Unique Feature:** It is the only AChEI available as a **transdermal patch**, which reduces gastrointestinal side effects (nausea/vomiting) and improves patient compliance. * **Other Alzheimer’s Drugs:** Donepezil and Galantamine are other AChEIs used. **Memantine** (an NMDA receptor antagonist) is used for moderate-to-severe cases. * **Side Effects:** Common side effects of these drugs are cholinergic in nature: diarrhea, urination, miosis, bradycardia, and salivation (DUMBELS).

Q: What are the CNS affections of a local anesthetic agent?

All of the above. **Explanation:** Local Anesthetic (LA) systemic toxicity (LAST) primarily affects the Central Nervous System (CNS) and the Cardiovascular system. CNS symptoms typically precede cardiovascular collapse because the brain is highly sensitive to sodium channel blockade. The progression of CNS toxicity follows a predictable pattern based on increasing plasma concentrations: 1. **Initial/Early Signs (Option B):** At low toxic levels, patients experience sensory changes such as **perioral numbness**, tingling of the tongue, a metallic taste, and tinnitus. This occurs due to the high vascularity of these areas and the sensitivity of cranial nerves. 2. **Excitatory Phase (Option A):** As levels rise, LAs selectively inhibit cortical inhibitory pathways (GABAergic neurons) while leaving excitatory pathways unopposed. This leads to agitation, muscle twitching, and eventually **grand mal convulsions**. 3. **Depressive Phase (Option C):** At very high concentrations, both inhibitory and excitatory pathways are inhibited, leading to generalized **CNS depression**. This manifests as unconsciousness, respiratory depression, and eventually coma. Since all three options represent different stages of the clinical spectrum of CNS toxicity, **Option D (All of the above)** is the correct answer. **High-Yield NEET-PG Pearls:** * **Potency vs. Toxicity:** Bupivacaine is more cardiotoxic than Lidocaine. The "CC/CNS ratio" (dose required for cardiovascular collapse vs. dose for convulsions) is lower for Bupivacaine, making it more dangerous. * **First Sign:** Perioral numbness/metallic taste is often the earliest warning sign of accidental intravascular injection. * **Management:** The specific antidote for LAST is **20% Intralipid (Lipid Emulsion Therapy)**. * **Hypercapnia/Acidosis:** Increases the risk of CNS toxicity by increasing cerebral blood flow (delivering more drug to the brain) and decreasing the seizure threshold.

Q: Which of the following is true about benzodiazepines?

GABA facilitator. **Explanation:** **1. Why "GABA Facilitator" is correct:** Benzodiazepines (BZDs) act as **positive allosteric modulators** of the GABA-A receptor. They bind to a specific site (the BZD site) located between the $\alpha$ and $\gamma$ subunits. Unlike barbiturates, BZDs do not activate the receptor directly; instead, they increase the **frequency** of chloride channel opening in the presence of GABA. This enhances the inhibitory effect of endogenous GABA, making them "GABA facilitators." **2. Why other options are incorrect:** * **A. GABA mimetic:** This term refers to drugs that can directly open chloride channels even in the absence of GABA (e.g., high-dose Barbiturates). BZDs lack this intrinsic activity, which is why they have a "ceiling effect" on CNS depression. * **C. Not a safe drug:** BZDs are considered relatively safe because of their high therapeutic index. Since they require endogenous GABA to work, they rarely cause fatal respiratory depression when taken alone (unlike barbiturates). * **D. High abuse potential:** While BZDs can lead to dependence, their abuse potential is categorized as **low to moderate** (Schedule IV) compared to opioids or barbiturates. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism Shortcut:** **B**enzodiazepines increase **F**requency (**B-F**); **B**arbiturates increase **D**uration (**B-D**) of channel opening. * **Antidote:** **Flumazenil** is a competitive BZD receptor antagonist used for overdose. * **Liver Metabolism:** For elderly patients or those with liver failure, use **LOT** drugs (**L**orazepam, **O**xazepam, **T**emazepam) as they undergo direct conjugation and do not form active metabolites. * **Drug of Choice:** BZDs are the DOC for **Status Epilepticus** (Lorazepam/Diazepam) and **Alcohol Withdrawal** (Chlordiazepoxide).

Q: Muscular rigidity caused by opioids is due to agonistic effect on which receptor?

Mu. **Explanation:** **1. Why Mu (μ) is Correct:** Opioid-induced muscle rigidity (often referred to as "Chest Wall Rigidity" or "Wooden Chest Syndrome") is primarily mediated by the **Mu (μ) opioid receptors**. This phenomenon occurs most frequently with rapid intravenous administration of potent lipophilic Mu-agonists like **Fentanyl, Sufentanil, and Remifentanil**. The underlying mechanism involves the activation of Mu receptors in the **striatum and substantia nigra** (basal ganglia), which modulates GABAergic and dopaminergic pathways, leading to increased motor neuron output and skeletal muscle contraction. **2. Why Other Options are Incorrect:** * **Kappa (κ):** These receptors are primarily associated with spinal analgesia, sedation, and miosis. Agonism here often leads to **dysphoria** and psychotomimetic effects, rather than muscular rigidity. * **Delta (δ):** These receptors contribute to supraspinal/spinal analgesia and may modulate emotional states. They do not play a significant role in motor rigidity. * **Sigma (σ):** Formerly classified as an opioid receptor, it is now considered a non-opioid chaperone protein. It is associated with hallucinations and mydriasis (e.g., by drugs like Pentazocine), but not classic opioid rigidity. **3. Clinical Pearls for NEET-PG:** * **Management:** The rigidity can be so severe that it prevents effective bag-mask ventilation. It is treated with **Neuromuscular Blocking Agents (e.g., Succinylcholine)** or the opioid antagonist **Naloxone**. * **High-Yield Fact:** Fentanyl is the most common culprit in clinical practice. * **Key Site:** The **Nucleus Raphe Pontis** is also implicated in the central mediation of this rigidity.

Q: Which of the following is NOT true about ester local anesthetics?

None of the above.. Local anesthetics (LAs) are chemically classified into two groups: **Esters** and **Amides**. This distinction is critical for understanding their metabolism, stability, and allergic potential. ### **Explanation of the Correct Answer** The correct answer is **D (None of the above)** because all the statements (A, B, and C) accurately describe the properties of ester local anesthetics. Since the question asks which statement is **NOT** true, and all are true, "None of the above" is the only logical choice. ### **Analysis of Options** * **Option A (Unstable in solution):** Esters possess a relatively weak chemical bond that is easily broken. They are heat-labile and have a shorter shelf-life compared to the highly stable amide group. * **Option B & C (Hydrolyzed in plasma by cholinesterase):** Unlike amides (which undergo slow hepatic metabolism), esters are rapidly hydrolyzed in the plasma by the enzyme **pseudocholinesterase** (butyrylcholinesterase). This results in a very short plasma half-life. ### **High-Yield Clinical Pearls for NEET-PG** * **Metabolite & Allergy:** Ester LAs are metabolized into **Para-aminobenzoic acid (PABA)**. PABA is highly immunogenic and is responsible for the allergic reactions associated with esters. Amides rarely cause true allergies. * **Pseudocholinesterase Deficiency:** Patients with atypical or deficient pseudocholinesterase are at risk of systemic toxicity due to the prolonged half-life of ester LAs. * **The "i" Rule:** To distinguish them easily—Amides have two "i"s in their name (L**i**doca**i**ne, Pr**i**loca**i**ne, Bup**i**vaca**i**ne), while Esters have only one "i" (Procaine, Chloroprocaine, Tetracaine, Benzocaine). * **Cocaine Exception:** Cocaine is the only ester LA that is primarily metabolized in the liver and also undergoes significant renal excretion.

Q: What is the mechanism of action of Levetiracetam?

Blocking SV2A protein. **Explanation:** **Mechanism of Action (Correct Answer: A)** Levetiracetam is a unique antiepileptic drug (AED) that does not act through traditional ion channel or GABAergic pathways. Its primary mechanism involves binding to the **Synaptic Vesicle Protein 2A (SV2A)**. This protein is located on the membranes of presynaptic vesicles and is involved in vesicle docking and fusion. By binding to SV2A, Levetiracetam modulates the release of neurotransmitters (specifically reducing the release of excitatory glutamate), thereby stabilizing neuronal excitability. **Analysis of Incorrect Options:** * **Option B (Inhibiting reuptake of GABA):** This is the mechanism of **Tiagabine**, which inhibits the GAT-1 transporter, increasing GABA concentration in the synaptic cleft. * **Option C (Inhibiting GABA transaminase):** This is the mechanism of **Vigabatrin**, which prevents the breakdown of GABA, leading to increased inhibitory levels. * **Option D (Calcium channel blocker):** This describes drugs like **Ethosuximide** (T-type Ca²⁺ channels) or **Gabapentin/Pregabalin** (α2δ subunit of N-type Ca²⁺ channels). **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacokinetics:** It has near 100% bioavailability, minimal protein binding, and is excreted unchanged in urine (no CYP450 involvement), making it ideal for patients on multiple medications. * **Side Effects:** The most characteristic side effect is **behavioral changes** (irritability, aggression, or "Levy-rage"). * **Clinical Use:** It is a broad-spectrum AED used for focal-onset seizures, myoclonic seizures (JME), and generalized tonic-clonic seizures. * **Brivaracetam:** A newer analog with a higher affinity for SV2A than Levetiracetam.

Question 1

Which anti-epileptic drug can be safely used in pregnancy?

Accepted Answer

Lamotrigine

Answer

Valproic acid

Answer

Phenytoin

Answer

Carbamazepine

Question 2

All of the following adverse effects are associated with carbamazepine except?

Accepted Answer

Decrease in antidiuretic hormone

Answer

Teratogenicity

Answer

Neurotoxicity

Answer

Hypersensitivity

Question 3

Which drug is primarily used in the management of Alzheimer's disease?

Accepted Answer

Rivastigmine

Answer

Tacrine

Answer

Pyridostigmine

Answer

Neostigmine

Question 4

What are the CNS affections of a local anesthetic agent?

Accepted Answer

All of the above

Answer

Convulsion

Answer

Perioral numbness

Answer

Depression

Question 5

Which of the following is true about benzodiazepines?

Accepted Answer

GABA facilitator

Answer

GABA mimetic

Answer

Not a safe drug

Answer

High abuse potential

Question 6

Muscular rigidity caused by opioids is due to agonistic effect on which receptor?

Accepted Answer

Mu

Answer

Kappa

Answer

Delta

Answer

Sigma

Question 7

Morphine can be administered by all of the following routes except:

Accepted Answer

Subarachnoid

Answer

Intramuscular

Answer

Transdermal

Answer

Epidural

Question 8

Which of the following is NOT true about ester local anesthetics?

Accepted Answer

None of the above.

Answer

They are unstable in solution.

Answer

They are hydrolyzed in plasma.

Answer

They are hydrolyzed by cholinesterase enzymes.

Question 9

True about anticonvulsants in pregnancy?

Accepted Answer

Monotherapy is generally recommended.

Answer

Carbamazepine is safe in pregnancy.

Answer

Lamotrigine is safe in pregnancy.

Answer

Newer anticonvulsant drugs are always safe in pregnancy.

Question 10

What is the mechanism of action of Levetiracetam?

Accepted Answer

Blocking SV2A protein

Answer

Inhibiting reuptake of GABA

Answer

Inhibiting GABA transaminase enzyme

Answer

Calcium channel blocker

Central Nervous System Pharmacology — MCQs

Central Nervous System Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?